VBI Vaccines jumps on hepatitis B shot approval

VBI Vaccines

01/12/2021 13:19

** Shares of vaccine maker  VBIV.O  jump ~12% to $3.41
premarket
    ** Co says U.S. FDA has approved its vaccine for prevention
of infection caused by all known subtypes of hepatitis B virus
(HBV) in adults aged 18 years and older  urn:newsml:reuters.com:*:nBw3sbj5Qa
    ** Approval of PreHevbrio based on results from two
late-stage studies that showed the vaccine elicited higher rates
of seroprotection in all subjects
    ** VBI expects to make PreHevbrio available in the U.S. in
Q1 of 2022
    ** Stock up 10.5% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))